Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin

Shares of Aradigm plunged, after the pharmaceutical company released mixed results for its inhaled antibiotic Pulmaquin. It used to treat chronic lung infections. In one of the late stage clinical trials, the company says it saw significant results while in the other it didn't. The principal investigator over the trials says it was exciting to see that after many setbacks in the development of inhaled antibiotics to treat these patients the company finally saw results with good safety and efficacy. But, investors apparently are not feeling as optimistic.